MAA
UTHR icon

Mraz Amerine & Associates’s United Therapeutics UTHR Stock Holding History

Mraz Amerine & Associates’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$244K Hold
450
– – 0.04% 162
2026
Q1 		$267K Hold
450
– – 0.04% 149
2025
Q4 		$219K Buy
+450
New +$210K 0.03% 163

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Mraz Amerine & Associates's UTHR Position: Q2 2026 in Review

Mraz Amerine & Associates held its United Therapeutics (UTHR) position steady in Q2 2026 at 450 shares worth $244K. The position accounts for 0.04% of the portfolio, ranked #162.

Mraz Amerine & Associates first reported a position in UTHR in Q4 2025 and has held it in 3 quarters since. The position peaked at $267K in Q1 2026. 878 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Mraz Amerine & Associates held 450 shares of United Therapeutics worth $244K as of Q2 2026.
  • Mraz Amerine & Associates left its United Therapeutics share count unchanged in Q2 2026.
  • United Therapeutics made up 0.04% of Mraz Amerine & Associates's portfolio in Q2 2026, its #162 holding.
  • Mraz Amerine & Associates first reported a position in United Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Mraz Amerine & Associates's United Therapeutics position peaked at $267K in Q1 2026.
  • 878 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Mraz Amerine & Associates's 13F filing for Q2 2026, filed 16 Jul 2026.